Alan P. Z. Skarbnik, MD, discusses the approval of brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma.
Alan P. Z. Skarbnik, MD, a hematologist/oncologist with Novant Health, discusses the approval of brexucabtagene autoleucel (Tecartus) in relapsed/refractory mantle cell lymphoma (MCL).
The ZUMA-2 trial evaluated brexucabtagene autoleucel in patients with relapsed/refractory MCL who previously received a BTK inhibitor, Skarbnik says. Notably, the CAR T-cell product induced an 87% objective response rate and a 62% complete response rate in this patient population.
However, the regulatory decision does not require patients to have had prior exposure to a BTK inhibitor, explains Skarbnik.
Although BTK inhibitors offer an effective therapy for patients with relapsed/refractory MCL, the majority of responses do not exceed 26 months, Skarbnik explains.
As such, the decision to approve brexucabtagene autoleucel for all patients with relapsed/refractory MCL may allow more patients to derive extended responses, concludes Skarbnik.